Abstract 13640: Baseline Kidney Function and the Effects of Dapagliflozin on Health Status in Heart Failure: A Pooled Patient-Level Analysis From DFEINE-HF and PRESERVED-HF
Andrew P Ambrosy, Andrew J Sauer, Shachi Patel, Sheryl Windsor, Barry A Borlaug, Mansoor Husain, Silvio E Inzucchi, Dalane W Kitzman, Darren K McGuire, Sanjiv J Shah, Kavita Sharma, Guillermo Umpierrez, Mikhail N Kosiborod- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Background: Sodium-glucose co-transport-2 (SGLT2) inhibitors have been shown to reduce clinical events and improve health status (symptoms, function, and quality of life) in patients with HF across the range of EF. Baseline kidney dysfunction is common in HF, complicates HF management, and is strongly linked to worse health status.
Aim: The study objective was to assess whether the treatment effects of dapagliflozin on health status vary based on baseline eGFR.
Methods: Patient-level data were pooled from the DEFINE-HF (N = 263 participants with EF
Results: Across both trials there were 583 (99.3%) participants with available baseline eGFR. The median (25 th , 75 th ) eGFR was 59 (46,77). Dapagliflozin improved KCCQ-CSS at 12 weeks (placebo-adjusted difference, +5.0 points, 95% Confidence Interval [CI] 2.6-7.5; p-value <0.001), and this was consistent in participants with an eGFR
Conclusion: Treatment with dapagliflozin for 12 weeks led to significant and consistent improvements in health-related quality of life in patients with HF across a wide range of eGFRs.